Nephropathic Cystinosis
Drug Use Review Documents
PDL Status Values
Y = preferred
N = non-preferred. Non-preferred drugs listed as N but without clinical drug use criteria are subject to the
Non-Preferred Drugs in Select PDL Classes prior authorization criteria.
New drugs will be listed as N until reviewed by the P&T Committee and are subject to the
New Drug Policy.
V = voluntary non-preferred. Non-preferred mental health drugs are listed as V and prior authorization is not required.
Null (i.e. blank) = indicates the class or specific drug has not been reviewed for PDL placement.
To request a Prior Authorization, please use this form.
| NDC | Brand Name | Generic Name | Form | Strength | PDL Status |
Rebate | Current Drug Use Criteria |
|---|---|---|---|---|---|---|---|
| 75987010004 | PROCYSBI | cysteamine bitartrate | CAP DR SPR | 25 mg | Y | PA Document | |
| 75987010108 | PROCYSBI | cysteamine bitartrate | CAP DR SPR | 75 mg | Y | PA Document | |
| 00378904505 | CYSTAGON | cysteamine bitartrate | CAPSULE | 150 mg | Y | ||
| 00378904005 | CYSTAGON | cysteamine bitartrate | CAPSULE | 50 mg | Y | ||
| 75987014513 | PROCYSBI | cysteamine bitartrate | GRANDR PKT | 300 mg | Y | PA Document | |
| 75987014013 | PROCYSBI | cysteamine bitartrate | GRANDR PKT | 75 mg | Y | PA Document |